Pericoronary fat attenuation index-a new imaging biomarker and its diagnostic and prognostic utility: a systematic review and meta-analysis.
FAI
computed tomography
fat attenuation index
imaging
major adverse cardiovascular events
prevention
unstable plaques
Journal
European heart journal. Cardiovascular Imaging
ISSN: 2047-2412
Titre abrégé: Eur Heart J Cardiovasc Imaging
Pays: England
ID NLM: 101573788
Informations de publication
Date de publication:
17 11 2022
17 11 2022
Historique:
received:
06
05
2022
accepted:
08
08
2022
pubmed:
8
9
2022
medline:
22
11
2022
entrez:
7
9
2022
Statut:
ppublish
Résumé
Pericoronary fat attenuation index (FAI) on coronary computed tomography angiography imaging has been proposed as a novel marker of coronary vascular inflammation with prognostic value for major cardiovascular events. To date, there is no systematic review of the published literature and no meta-analysed data of previously published results. We performed a systematic review and meta-analysis according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines. We systematically explored published literature in MEDLINE (PubMed) before 20 January 2022 for studies assessing FAI in both diagnostic and prognostic clinical settings in patients with or without cardiovascular disease. The primary outcome was the mean difference in FAI attenuation between stable and unstable coronary plaques. The secondary outcome was the hazard ratio (HR) of high FAI values for future cardiovascular events. We calculated I2 to test heterogeneity. We used random-effects modelling for the meta-analyses to assess the primary and secondary outcomes. This study is registered with PROSPERO (CRD42021229491). In total, 20 studies referred in a total of 7797 patients were included in this systematic review, while nine studies were used for the meta-analysis. FAI was significantly higher in unstable compared with stable plaques with a mean difference of 4.50 Hounsfield units [95% confidence interval (CI): 1.10-7.89, I2 = 88%] among 902 patients. Higher pericoronary FAI values offered incremental prognostic value for major adverse cardiovascular events (MACEs) in studies with prospective follow-up (HR = 3.29, 95% CI: 1.88-5.76, I2 = 75%) among 6335 patients. Pericoronary FAI seems to be a promising imaging biomarker that can be used for the detection of coronary inflammation, possibly to discriminate between stable and unstable plaques, and inform on the prognosis for future MACE. Further validation of these findings and exploration of the cost-effectiveness of the method before implementation in clinical practice are needed.
Identifiants
pubmed: 36069510
pii: 6693607
doi: 10.1093/ehjci/jeac174
pmc: PMC9840478
doi:
Substances chimiques
Biomarkers
0
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e526-e536Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Déclaration de conflit d'intérêts
Conflict of interest: None declared.
Références
J Cardiovasc Comput Tomogr. 2020 Nov - Dec;14(6):483-489
pubmed: 32057707
Eur Radiol. 2020 Feb;30(2):673-681
pubmed: 31444596
JACC Cardiovasc Imaging. 2021 Aug;14(8):1598-1610
pubmed: 33958312
Atherosclerosis. 2018 Sep;276:182-188
pubmed: 29866393
J Am Heart Assoc. 2019 Sep 3;8(17):e013235
pubmed: 31462127
Annu Rev Immunol. 2009;27:165-97
pubmed: 19302038
Eur Heart J Cardiovasc Imaging. 2019 Jun 1;20(6):636-643
pubmed: 30789223
Heart Fail Clin. 2016 Jan;12(1):1-10
pubmed: 26567971
JACC Cardiovasc Imaging. 2020 Nov;13(11):2371-2383
pubmed: 32861654
J Comput Assist Tomogr. 2017 Sep/Oct;41(5):762-767
pubmed: 28914752
Int J Mol Sci. 2021 Dec 15;22(24):
pubmed: 34948272
Curr Cardiol Rep. 2020 Jul 9;22(9):90
pubmed: 32647932
Vasa. 2022 Jul;51(4):198-211
pubmed: 35673949
J Atheroscler Thromb. 2018 Apr 1;25(4):294-303
pubmed: 29238011
Circulation. 2019 Mar 26;139(13):1581-1592
pubmed: 30586731
Eur Heart J. 2019 Nov 14;40(43):3529-3543
pubmed: 31504423
Eur Heart J Cardiovasc Imaging. 2020 Jun 1;21(6):599-605
pubmed: 32091086
Int J Mol Sci. 2021 Jun 21;22(12):
pubmed: 34205487
J Cardiovasc Comput Tomogr. 2018 Sep - Oct;12(5):436-443
pubmed: 30017608
PLoS Med. 2009 Jul 21;6(7):e1000100
pubmed: 19621070
JACC Cardiovasc Imaging. 2018 Oct;11(10):1475-1484
pubmed: 29909109
Med Monatsschr Pharm. 2017 Apr;40(4):175-7
pubmed: 29952172
Lancet. 2018 Sep 15;392(10151):929-939
pubmed: 30170852
Int J Cardiol. 2020 Nov 15;319:144-149
pubmed: 32553595
JAMA Cardiol. 2019 Sep 1;4(9):885-891
pubmed: 31365032
J Cell Physiol. 2019 Aug;234(10):16812-16823
pubmed: 30790284
J Am Heart Assoc. 2020 Sep;9(17):e016504
pubmed: 32856503
Circulation. 2020 Mar 3;141(9):e139-e596
pubmed: 31992061
JAMA Cardiol. 2018 Sep 1;3(9):858-863
pubmed: 30027285
Cardiovasc Res. 2022 Jul 27;118(10):2281-2292
pubmed: 34358302
Circ Res. 2017 Jan 6;120(1):229-243
pubmed: 28057795
Am J Lifestyle Med. 2016 Jan 19;12(2):130-139
pubmed: 30202385
Circulation. 2015 Jan 13;131(2):211-9
pubmed: 25561516
N Engl J Med. 2005 Apr 21;352(16):1685-95
pubmed: 15843671
Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):1806-1812
pubmed: 33200300
Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):1707-1708
pubmed: 33398410
J Am Heart Assoc. 2020 Aug 4;9(15):e016202
pubmed: 32750306
Curr Atheroscler Rep. 2019 Nov 19;21(12):47
pubmed: 31741080
J Am Coll Cardiol. 2018 Jan 30;71(4):414-425
pubmed: 29389358
Sci Transl Med. 2017 Jul 12;9(398):
pubmed: 28701474
JACC Cardiovasc Imaging. 2019 Oct;12(10):2000-2010
pubmed: 30772226
Curr Atheroscler Rep. 2020 Oct 6;22(12):75
pubmed: 33025148
Curr Atheroscler Rep. 2017 Sep 18;19(11):42
pubmed: 28921056
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120